New hope for Tough-to-Treat myeloma: cevostamab trial opens
NCT ID NCT05535244
First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests an experimental drug called cevostamab in people with multiple myeloma that has returned or not responded to other treatments. About 90 participants who have already tried a type of BCMA-targeted therapy will receive the drug through an IV. The goal is to see if the drug can shrink tumors and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette
Turin, Piedmont, 10126, Italy
-
APHP - Hospital Saint Louis
Paris, 75475, France
-
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, 24127, Italy
-
CHU NANTES - Hôtel Dieu
Nantes, 44093, France
-
CHU de Poitiers - La Miletrie
Poitiers, 86021, France
-
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, 20133, Italy
-
Hadassah Ein Karem Hospital
Jerusalem, 9112001, Israel
-
Hospital Clínic i Provincial
Barcelona, 08036, Spain
-
Hospital Univ. 12 de Octubre
Madrid, 28041, Spain
-
Hunstman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, 10029, United States
-
Klinik der Uni zu Köln
Cologne, 50924, Germany
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, 40138, Italy
-
Sheba Medical Center
Ramat Gan, 5262100, Israel
-
Sourasky Medical Centre
Tel Aviv, 6423906, Israel
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
University of Colorado
Aurora, Colorado, 80045-2517, United States
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
Hamburg, 20246, Germany
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
Conditions
Explore the condition pages connected to this study.